Suramin inhibits proliferation of human arterial smooth muscle cells in vitro: Potential drug for prevention of restenosis by local drug delivery

Journal of Vascular and Interventional Radiology

Volumn 11, Issue 5, 2000, Pages 639-644

  Engisch, Renate ^a,d   Schürmann, Karl ^b   Bienert, Hans ^b   Vom Dahl, Jürgen ^b   Voss, Meinolf ^b   Günther, Rolf W ^b   Vorwerk, Dierk ^c  

^a Central Hospital   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c KLINIKUM INGOLSTADT   (Germany)

^d Center Hospital   (Germany)

Author keywords

Angioplasty, complications; Neointima; Restenosis; Smooth muscle cells

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SURAMIN;

ARTERY INTIMA PROLIFERATION; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 0342424349     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61619-4     Document Type: Article

References (37)

1. Gruentzig A, Senning A, Siegenthalter WE. Nonoperative dilatation of coronary artery stenosis, percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301:61-68.
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316:701-706.
3. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331:496-501.
4. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995; 25:516-520.
5. Schwartz SM, deBlois D, O'Brien ERM. The intima. Soil for atherosclerosis and restenosis. Circulation Res 1995; 77:445-465.
6. McLeod DC, Strauss BH, de Jong M, et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994; 23:59-65.
7. Libby P, Schwartz D, Brog E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation 1992; 86:47-52.
8. Schwartz SM, Reidy MA, O'Brien ERM. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemostas 1995; 74:541-551.
9. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991; 88: 3739-3743.
10. Olson NE, Chao S, Lindner V, Reidy MA. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am J Pathol 1992; 140:1017-1023.
11. Bell L, Madri JA. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circulation Res 1989; 65:1057-1065.
12. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimai thickening in rat model of balloon angioplasty. J Clin Invest 1992; 89:507-511.
13. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17:758-769.
14. Chen JK, Hoshi H, McKeenan WL. Transforming growth factor type β specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci U S A 1987; 84:5287-5291.
15. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor β1 during repair of arterial injury. J Clin Invest 1991; 88:904-910.
16. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-1293.
17. Laporte S, Escher E. Neointima formation after vascular injury is angiotensin II mediated. Biochem Biophys Res Comm 1992; 187:1510-1516.
18. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle hypertrophy vs. hyperplasia: autocrine growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90:456-461.
19. Koibuchi Y, Lee WS, Gibbons GH, Pratt RE. Role of transforming growth factor-β1 in the cellular growth response to angiotensin II. Hypertension 1993; 21:1046-1050.
20. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-2274.
21. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1419-1424.
22. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7:499-508.
23. Middaugh RC, Mach H, Burke CJ, et al. Nature of the interaction of growth factors with Suramin. Biochemistry 1992; 31:9016-9024.
24. Asada Y, Tsuneyoshi A, Marutsuka K, Sumiyoshi A. Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo. Cardiovasc Res 1994; 28:1166-1169.
25. Okamoto S, Inden M, Setsuda M, Konichi T, Nakano T. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123:1439-1444.
26. Olson NE, Chao S, Lindner V, Reidy MA. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am J Pathol 1992; 140:1017-1023.
27. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93:1172-1178.
28. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 1996; 93:848-852.
29. Taylor CW, Luui R, Fanta P, Salmon SE. Effects of Suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 1992; 84:489-494.
30. Cardinali M, Sartor O, Robbins KC. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J Clin Invest 1992; 89:1242-1247.
31. Mietz H, Chévez-Barrios P, Lieberman MW, Wendt, M, Gross R, Basinger SF. Decorin and suramin inhibit ocular fibroblast collagen production. Graefe's Arch Clin Exp Ophthalmol 1997; 235: 399-403.
32. Danesi R, Del Bianchi S, Soldani P, et al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993; 68:932-938.
33. Cooper MR, Lieberman R, LaRocca RV, et al. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther 1992; 52:11-23.
34. Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, Figg WD. Suramin-induced neutropenia. Eur J Cancer 1996; 32A: 1534-1539.
35. Laemmel E, Penhoat J, Warocquier-Clérout R, Sigot-Luizard M-F. Heparin immobilized on proteins usable for arterial prosthesis coating: growth inhibition of smooth-muscle cells. J Biomed Mater Res 1998; 39:446-452.
36. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29: 808-816.
37. Alfke H, Wagner H-J, Calmer C, Klose KJ. Local intravascular drug delivery: in vitro comparison of three catheter systems. Cardiovasc Intervent Radiol 1998; 21:50-56.